Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Enoblituzumab (DHJ04001)

Host species:Humanized
Isotype:IgG1-kappa
Applications:Research Grade Biosimilar
Expression system:Mammalian Cells
Overview

Catalog No.

DHJ04001

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

CD276, B7-H3, Costimulatory molecule, B7H3, 4Ig-B7-H3, B7 homolog 3, CD276 antigen

Concentration

2.04 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

Q5ZPR3

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

MG-A271, CAS: 1353485-38-7

Clone ID

Enoblituzumab

Data Image
  • Bioactivity
    Detects Human CD276 in indirect ELISAs.
  • SDS-PAGE
    SDS PAGE for Enoblituzumab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Correlation of B7-H3 with androgen receptor, immune pathways and poor outcome in prostate cancer: an expression-based analysis PMID: 27801901

A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature. PMID: 28399405

Development of an Fc-enhanced anti-B7-H3 monoclonal antibody with potent antitumor activity. PMID: 22615450

Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC). PMID: 30850021

A Platform for Extracellular Interactome Discovery Identifies Novel Functional Binding Partners for the Immune Receptors B7-H3/CD276 and PVR/CD155. PMID: 31308249

Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. PMID: 30027617

Autophagy promotes citrullination of VIM (vimentin) and its interaction with major histocompatibility complex class II in synovial fibroblasts. PMID: 31486697

MicroRNA-187 inhibits tumor growth and invasion by directly targeting CD276 in colorectal cancer. PMID: 27329595

TREM and TREM-like receptors in inflammation and disease. PMID: 19230638

B7-H3: a costimulatory molecule for T cell activation and IFN-gamma production. PMID: 11224528

Removal of CD276(+) cells from haploidentical memory T-cell grafts significantly lowers the risk of GVHD. PMID: 33976380

Immune profile and immunosurveillance in treatment-naive and neoadjuvantly treated esophageal adenocarcinoma. PMID: 31960110

Genome-wide association study identifies loci influencing concentrations of liver enzymes in plasma. PMID: 22001757

In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment. PMID: 33925968

LncRNA NEAT1 sponges miR-214 to regulate M2 macrophage polarization by regulation of B7-H3 in multiple myeloma. PMID: 31731055

B7-H3 Expression in NSCLC and Its Association with B7-H4, PD-L1 and Tumor-Infiltrating Lymphocytes. PMID: 28539467

B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3. PMID: 30573782

Soluble CD276 (B7-H3) is released from monocytes, dendritic cells and activated T cells and is detectable in normal human serum. PMID: 18194267

HHLA2 is a novel prognostic predictor and potential therapeutic target in malignant glioma. PMID: 31578594

A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment. PMID: 33057845

CD70 as a target for chimeric antigen receptor T cells in head and neck squamous cell carcinoma. PMID: 29496042

Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. PMID: 28024695

High expression of cluster of differentiation 276 indicates poor prognosis in glioma. PMID: 34366684

WITHDRAWN: Tumor B7-H3 (CD276) expression and smoking history in relation to lung adenocarcinoma prognosis. PMID: 27721121

Circulating B7-H3(CD276) elevations in cerebrospinal fluid and plasma of children with bacterial meningitis. PMID: 18690554

Regulation of Immunity by Butyrophilins. PMID: 26772212

Decreased m6A Modification of CD34/CD276(B7-H3) Leads to Immune Escape in Colon Cancer. PMID: 34307389

New checkpoints in cancer immunotherapy. PMID: 28258699

B7-H3: A promising therapeutic target for autoimmune diseases. PMID: 32113615

B7-H3 and its role in bone cancers. PMID: 31060912

Correlation of PD-L1 and SOCS3 Co-expression with the Prognosis of Hepatocellular Carcinoma Patients. PMID: 32742491

Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody. PMID: 34601396

Isolation and characterization of CD276+/HLA-E+ human subendocardial mesenchymal stem cells from chronic heart failure patients: analysis of differentiative potential and immunomodulatory markers expression. PMID: 23013234

Stimulation of B7-H3 (CD276) directs the differentiation of human marrow stromal cells to osteoblasts. PMID: 21893365

Gene clusters based on OLIG2 and CD276 could distinguish molecular profiling in glioblastoma. PMID: 34565408

Expression status of PD-L1 and B7-H3 in mesothelioma. PMID: 33027549

Clinical relevance of B7H3 expression in retinoblastoma. PMID: 32576886

Magnetic Bead-Immobilized Mammalian Cells Are Effective Targets to Enrich Ligand-Displaying Yeast. PMID: 32283920

B7-H3-mediated tumor immunology: Friend or foe? PMID: 24013874

T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting. PMID: 31267380

Costimulation, coinhibition and cancer. PMID: 17305475

B7-H3 in Medulloblastoma-Derived Exosomes; A Novel Tumorigenic Role. PMID: 32992699

Frequent B7-H3 overexpression in craniopharyngioma. PMID: 31043272

Profiling of inhibitory immune checkpoints in glioblastoma: Potential pathogenetic players. PMID: 33123243

The Adaptive and Innate Immune Cell Landscape of Uterine Leiomyosarcomas. PMID: 31959856

B7-H3 in tumors: friend or foe for tumor immunity? PMID: 29299639

Correction: PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma. PMID: 33931605

Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies. PMID: 28622628

Isolation of rabbit single domain antibodies to B7-H3 via protein immunization and phage display. PMID: 32166218

The role of B7 family molecules in hematologic malignancy. PMID: 23223433

Co-inhibitory immune checkpoints in head and neck squamous cell carcinoma. PMID: 29480599

Datasheet

Document Download

Research Grade Enoblituzumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Enoblituzumab [DHJ04001]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2024 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only